Risks of sparsentan interactions with other drugs

Sparsentan, an innovative drug developed by the American companyTravere Therapeutics, has received widespread attention from the medical community for its excellent performance in the treatment of primary immunoglobulin A nephropathy (IgAN). However, like many highly effective drugs, spaxentan can have a complex set of interactions when used with other drugs.

The primary concern is the possible risks associated with the combined use of sparsentane with certain medications. For example, when sparsentane is used concomitantly with drugs such as renin-angiotensin system (RAS) inhibitors, endothelin receptor antagonists (ERA), or aliskiren, patients may be at increased risk of hypotension, syncope, hyperkalemia, and fluctuations in renal function. Therefore, patients are required to discontinue these medications before initiating treatment with sparsentane to ensure the safety of treatment.

Furthermore, the metabolism of sparsentane is closely related to the cytochromeP450 (CYP) enzyme system, especially CYP3A. Strong and moderate CYP3A inhibitors may interfere with the normal metabolism of sparsentan, leading to abnormal increases in its blood concentration, thereby increasing the risk of adverse reactions. For this reason, concomitant use of sparsentane with these inhibitors should be avoided. If necessary, patients need to be closely monitored and drug dosage adjusted according to actual conditions.

In addition, spaxentan may affect other medications. Specifically, it may reduce the plasma concentrations of drugs metabolized by CYP2B6, 2C9 and 2C19, thus affecting the efficacy of these drugs. Therefore, during sparsentan treatment, doctors need to conduct a comprehensive evaluation of other drugs that the patient is taking and make appropriate adjustments based on the actual drug interactions.

In summary, the interaction between sparsentane and other drugs is an issue that requires great attention. In order to ensure the safety and effectiveness of the patient's treatment, doctors should inquire about the patient's medication status in detail before prescribing sparsentane, comprehensively assess potential drug interaction risks, and maintain close monitoring throughout the treatment process. At the same time, patients should strictly follow the doctor's instructions and are not allowed to change the dosage or combination of drugs without authorization.